Acute pancreatitis remains a serious cause of ERCP-related morbidity.
In this study, physicians from the United States evaluated the effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis.
They also examined the ease of cannulation and severity of post-ERCP pancreatitis.
The team randomized 326 patients undergoing ERCP to receive either 10 mL of 1% lidocaine or saline. The solution was sprayed on the major papilla before cannulation.
Patients were observed for the development of post-ERCP pancreatitis.
|Ease of cannulation did not differ between the 2 groups.|
There were 32 patients who were excluded from the study after randomization.
A total of 294 patients were analyzed.
The physicians did not find any significant differences in patient history- or procedure-related variables.
Overall, 7 patients in the lidocaine group and 5 in the placebo group developed post-ERCP pancreatitis.
Furthermore, the team did not find that ease of cannulation differed between the 2 groups.
Dr Jeremy Schwartz's team concluded, "Lidocaine sprayed on the major papilla does not decrease the frequency of post-ERCP pancreatitis".